Clinical Trial Update: A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating pembrolizumab with or without lenvatinib as first-line therapy in PD-L1–selected recurrent or metastatic head and neck squamous cell ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2024-10-18